Issue

Vol. 2 No. 2 (2025)

Date Log

Submitted
July 19, 2026
Published
December 31, 2025

Copyright (c) 2025 Naif Hassan Almazrou, Emad Alawy Sharahily, Amal Abdullah Ali Alomran, Samer Olaythah Ahmed Alsubhi, Samy Fhaid Sulaiman Alsamy, Atiaf Fatehaldein Ali Yousef, Fatemah Hassan Mobarki, Mansour Ahmed Salman Amri, Manal Abdullah Ali Aldosari, Zainab Abdullah Saleh Albishi, Meaad Ali Mohammed Buayti

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Interdisciplinary Diagnosis and Management of Colorectal Cancer for Nursing, Radiology, Laboratory, Nutrition, and Health Informatics Professionals

https://doi.org/10.64483/202522743
Naif Hassan Almazrou
Third Health Cluster, Ministry of Health, Saudi Arabia
Emad Alawy Sharahily
King Abdulaziz Medical City, Jeddah, Ministry of National Guard Health Affairs, Saudi Arabia
Amal Abdullah Ali Alomran
Al-Mazrou Primary Health Care Center, Al-Ahsa Health Cluster, Ministry of Health, Saudi Arabia
Samer Olaythah Ahmed Alsubhi
Badr General Hospital, Ministry of Health, Saudi Arabia
Samy Fhaid Sulaiman Alsamy
Inventory Control Department, Hail Health Cluster, Ministry of Health, Saudi Arabia
Atiaf Fatehaldein Ali Yousef
Al-Malz Primary Health Care Center, First Health Cluster, Riyadh, Ministry of Health, Saudi Arabia
Fatemah Hassan Mobarki
Al-Mawsam General Hospital, Jazan Health Cluster, Ministry of Health, Saudi Arabia
Mansour Ahmed Salman Amri
Mu'taq Al-'Asam Primary Health Care Center, Jazan, Ministry of Health, Saudi Arabia
Manal Abdullah Ali Aldosari
Al-Sulayyil General Hospital, Ministry of Health, Saudi Arabia
Zainab Abdullah Saleh Albishi
Al-Sulayyil General Hospital, Ministry of Health, Saudi Arabia
Meaad Ali Mohammed Buayti
Al-Salam Endowment Hospital, Madinah, Ministry of Health, Saudi Arabia

Corresponding Author(s) : Naif Hassan Almazrou

naifhassan2020@gmail.com

Saudi Journal of Medicine and Public Health, Vol. 2 No. 2 (2025)

Abstract

Colorectal cancer (CRC) remains a significant global health burden, ranking as the third most commonly diagnosed malignancy and the second leading cause of cancer-related mortality worldwide. The complex molecular landscape, heterogeneous presentation, and multifaceted treatment approaches necessitate a collaborative, interdisciplinary framework for optimal patient outcomes. This comprehensive review synthesizes current evidence on CRC pathophysiology, risk factors, diagnostic modalities, and therapeutic strategies while emphasizing the critical roles of nursing, radiology, laboratory medicine, and health informatics professionals in the multidisciplinary care team. Recent advances in genomics, epigenetics, metabolic reprogramming, and artificial intelligence have revolutionized CRC diagnosis and management, creating both opportunities and challenges for healthcare professionals across specialties. The integration of molecular biomarkers, advanced imaging techniques, patient-derived organoids, and computational approaches has enabled more precise risk stratification, early detection, and personalized treatment selection. However, disparities in screening participation, healthcare access, and implementation of novel technologies persist. This review provides a framework for interdisciplinary collaboration, highlighting how nursing professionals can optimize patient education and supportive care, radiology experts can enhance diagnostic accuracy through advanced imaging and radiomics, laboratory specialists can facilitate molecular characterization and biomarker-guided therapy, and health informatics professionals can leverage artificial intelligence and data integration to improve clinical decision-making. By fostering effective communication and coordinated care across disciplines, healthcare systems can address the multifaceted challenges of CRC management and improve patient outcomes.

Keywords

Colorectal cancer, interdisciplinary care, nursing, radiology, laboratory medicine, health informatics, molecular diagnostics, artificial intelligence, targeted therapy, precision medicine
Almazrou, N. H., Sharahily, E. A., Alomran, A. A. A., Alsubhi, S. O. A., Alsamy, S. F. S., Yousef, A. F. A., … Buayti, M. A. M. (2025). Interdisciplinary Diagnosis and Management of Colorectal Cancer for Nursing, Radiology, Laboratory, Nutrition, and Health Informatics Professionals. Saudi Journal of Medicine and Public Health, 2(2), 3785–3797. https://doi.org/10.64483/202522743
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. [1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49.
  2. [2] Morgan E, Arnold M, Gini A, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023;72(2):338-344.
  3. [3] Matsuda T, Fujimoto A, Igarashi Y. Colorectal Cancer: Epidemiology, Risk Factors, and Public Health Strategies. 2025;106:91-99.
  4. [4] Huang Z, Yang M. Molecular Network of Colorectal Cancer and Current Therapeutic Options. Front Oncol. 2022;12:852927.
  5. [5] Nguyen LH, Goel A, Chung DC. Pathways of Colorectal Carcinogenesis. Gastroenterology. 2020;158(2):291-302.
  6. [6] Ceccon C, Borga C, Angerilli V, et al. MLH1 gene promoter methylation status partially overlaps with CpG methylator phenotype (CIMP) in colorectal adenocarcinoma. Pathol Res Pract. 2025;266:155786.
  7. [7] Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350-1356.
  8. [8] Valdeolivas A, Amberg B, Giroud N, et al. Profiling the heterogeneity of colorectal cancer consensus molecular subtypes using spatial transcriptomics. NPJ Precis Oncol. 2024;8:10.
  9. [9] Andre T, Shiu KK, Kim TW, et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020;383:2207-2218.
  10. [10] Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med. 2019;381:1632-1643.
  11. [11] Wang Q, Shen X, Chen G, Du J. How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation. Int J Cancer. 2023;153:709-722.
  12. [12] Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology. 2010;138(6):2044-58.
  13. [13] Li J, Ma X, Chakravarti D, Shalapour S, DePinho RA. Genetic and biological hallmarks of colorectal cancer. Genes Dev. 2021;35:787-820.
  14. [14] Vieira AR, Abar L, Chan DSM, et al. Foods and beverages and colorectal cancer risk: a systematic review and meta-analysis of cohort studies. Ann Oncol. 2017;28(8):1788-1802.
  15. [15] Takachi R, Tsubono Y, Baba K, et al. Red meat intake may increase the risk of colon cancer in Japanese, a population with relatively low red meat consumption. Asia Pac J Clin Nutr. 2011;20(4):603-12.
  16. [16] Bagnardi V, Rota M, Botteri E, et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br J Cancer. 2015;112(3):580-93.
  17. [17] Mizoue T, Inoue M, Wakai K, et al. Alcohol drinking and colorectal cancer in Japanese: a pooled analysis of results from five cohort studies. Am J Epidemiol. 2008;167(12):1397-406.
  18. [18] Botteri E, Borroni E, Sloan EK, et al. Smoking and colorectal cancer risk, overall and by molecular subtypes: a meta-analysis. Am J Gastroenterol. 2020;115(12):1940-9.
  19. [19] Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019;16(12):713-32.
  20. [20] Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(22):1679-87.
  21. [21] Otani T, Iwasaki M, Sasazuki S, et al. Plasma C-peptide, insulin-like growth factor-I, insulin-like growth factor binding proteins and risk of colorectal cancer in a nested case-control study. Int J Cancer. 2007;120(9):2007-12.
  22. [22] Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10(6):639-45.
  23. [23] Porter RJ, Arends MJ, Churchhouse AMD, Din S. Inflammatory bowel disease-associated colorectal cancer: translational risks from mechanisms to medicines. J Crohns Colitis. 2021;15(12):2131-41.
  24. [24] Birch RJ, Burr N, Subramanian V, et al. Inflammatory bowel disease-associated colorectal cancer epidemiology and outcomes: an English population-based study. Am J Gastroenterol. 2022;117(11):1858-70.
  25. [25] Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759-767.
  26. [26] Tejeda-Munoz N, Mei KC. Wnt signaling in cell adhesion, development, and colon cancer. IUBMB Life. 2024;76:383-396.
  27. [27] Zhu G, Pei L, Xia H, Tang Q, Bi F. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer. 2021;20:143.
  28. [28] Liebl MC, Hofmann TG. The Role of p53 Signaling in Colorectal Cancer. Cancers (Basel). 2021;13:2125.
  29. [29] Gallois C, Laurent-Puig P, Taieb J. Methylator phenotype in colorectal cancer: A prognostic factor or not? Crit Rev Oncol Hematol. 2016;99:74-80.
  30. [30] Okugawa Y, Grady WM, Goel A. Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers. Gastroenterology. 2015;149(5):1204-1225.
  31. [31] Garmpis N, Damaskos C, Garmpi A, et al. Histone Deacetylases and their Inhibitors in Colorectal Cancer Therapy. Curr Med Chem. 2022;29(17):2979-2994.
  32. [32] Kogo R, Shimamura T, Mimori K, et al. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res. 2011;71(20):6320-6326.
  33. [33] La Vecchia S, Sebastian C. Metabolic pathways regulating colorectal cancer initiation and progression. Semin Cell Dev Biol. 2020;98:63-70.
  34. [34] Jiang M, Liu S, Lin J, et al. A pan-cancer analysis of molecular characteristics and oncogenic role of hexokinase family genes in human tumors. Life Sci. 2021;264:118669.
  35. [35] Cha PH, Hwang JH, Kwak DK, et al. APC loss induces Warburg effect via increased PKM2 transcription in colorectal cancer. Br J Cancer. 2021;124(3):634-644.
  36. [36] Zaytseva YY. Lipid Metabolism as a Targetable Metabolic Vulnerability in Colorectal Cancer. Cancers (Basel). 2021;13(2):301.
  37. [37] Wen J, Min X, Shen M, et al. ACLY facilitates colon cancer cell metastasis by CTNNB1. J Exp Clin Cancer Res. 2019;38:401.
  38. [38] Quan J, Cheng C, Tan Y, et al. Acyl-CoA synthetase long-chain 3-mediated fatty acid oxidation is required for TGFβ1-induced epithelial-mesenchymal transition and metastasis of colorectal carcinoma. Int J Biol Sci. 2022;18(6):2484-2496.
  39. [39] Tran TQ, Hanse EA, Habowski AN, et al. α-Ketoglutarate attenuates Wnt signaling and drives differentiation in colorectal cancer. Nat Cancer. 2020;1(3):345-358.
  40. [40] Wong CC, Xu J, Bian X, et al. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling. Gastroenterology. 2020;159(6):2163-2180.e6.
  41. [41] Zhao Y, Feng X, Chen Y, et al. 5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against PIK3CA-Mutant Colorectal Cancers. Cancer Res. 2020;80:4815-4827.
  42. [42] Martelli V, Pastorino A, Sobrero AF. Prognostic and predictive molecular biomarkers in advanced colorectal cancer. Pharmacol Ther. 2022;236:108239.
  43. [43] Deming DA. Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer. J Natl Compr Canc Netw. 2025;23:e247067.
  44. [44] Kolisnik T, Sulit AK, Schmeier S, et al. Identifying important microbial and genomic biomarkers for differentiating right- versus left-sided colorectal cancer using random forest models. BMC Cancer. 2023;23:647.
  45. [45] Asghari-Jafarabadi M, Wilkins S, Plazzer JP, et al. Prognostic factors and survival disparities in right-sided versus left-sided colon cancer. Sci Rep. 2024;14:12306.
  46. [46] Kim N, Lee ES, Won SE, et al. Evolution of Radiological Treatment Response Assessments for Cancer Immunotherapy. Korean J Radiol. 2022;23:1089-1101.
  47. [47] Foersch S, Glasner C, Woerl AC, et al. Multistain deep learning for prediction of prognosis and therapy response in colorectal cancer. Nat Med. 2023;29:430-439.
  48. [48] Sun R, Limkin EJ, Vakalopoulou M, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy. Lancet Oncol. 2018;19:1180-1191.
  49. [49] Fan A, Wang B, Wang X, et al. Immunotherapy in colorectal cancer: current achievements and future perspective. Int J Biol Sci. 2021;17:3837-3849.
  50. [50] Yazdani A, Yazdani A, Mendez-Giraldez R, et al. Gene expression biomarkers differentiate overall survival of colorectal cancer upon targeted therapies. Res Sq. 2024.
  51. [51] Patel SG, Karlitz JJ, Yen T, et al. The rising tide of early-onset colorectal cancer: a comprehensive review. Lancet Gastroenterol Hepatol. 2022;7:262-274.
  52. [52] Lafarge MW, Domingo E, Sirinukunwattana K, et al. Image-based consensus molecular subtyping in rectal cancer biopsies and response to neoadjuvant chemoradiotherapy. NPJ Precis Oncol. 2024;8:89.
  53. [53] Martins D, Rodrigues J, Redondo P, et al. Evaluating the Optimal Sequence of Treatment with EGFR Inhibitors and Bevacizumab in RAS Wild-Type Metastatic Colorectal Cancer. Cureus. 2022;14:e23543.
  54. [54] Yi K, Park SH, Kim DU, et al. Patient-derived Organoid Model for Predicting the Chemoresponse in Patients With Colorectal Cancer. In Vivo. 2023;37:1751-1759.
  55. [55] Durinikova E, Buzo K, Arena S. Preclinical models as patients' avatars for precision medicine in colorectal cancer. J Exp Clin Cancer Res. 2021;40:185.
  56. [56] Ruusuvuori P, Valkonen M, Latonen L. Deep learning transforms colorectal cancer biomarker prediction from histopathology images. Cancer Cell. 2023;41:1543-1545.
  57. [57] Sirinukunwattana K, Domingo E, Richman SD, et al. Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning. Gut. 2021;70:544-554.
  58. [58] Zamanitajeddin N, Jahanifar M, Bilal M, et al. Social network analysis of cell networks improves deep learning for prediction of molecular pathways and key mutations in colorectal cancer. Med Image Anal. 2024;93:103071.
  59. [59] Vayrynen JP, Lau MC, Haruki K, et al. Prognostic Significance of Immune Cell Populations Identified by Machine Learning in Colorectal Cancer. Clin Cancer Res. 2020;26:4326-4338.
  60. [60] Das K, Paltani M, Tripathi PK, et al. Current implications and challenges of artificial intelligence technologies in therapeutic intervention of colorectal cancer. Expert Antitumor Ther. 2023;4:1286-1300.
  61. [61] Schulz S, Jesinghaus M, Foersch S. Multistain deep learning as a prognostic and predictive biomarker in colorectal cancer. Pathologie. 2023;44:104-108.
  62. [62] Prelaj A, Miskovic V, Zanitti M, et al. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review. Ann Oncol. 2024;35:29-65.
  63. [63] Ding X, Huang H, Fang Z, Jiang J. From Subtypes to Solutions: Integrating CMS Classification with Precision Therapeutics in Colorectal Cancer. Curr Treat Options Oncol. 2024;25:1580-1593.
  64. [64] Dougherty MK, Brenner AT, Crockett SD, et al. Evaluation of interventions intended to increase colorectal cancer screening rates in the United States: a systematic review and meta-analysis. JAMA Intern Med. 2018;178(12):1645-58.
  65. [65] Mishra I, Gupta K, Mishra R, et al. An Exploration of Organoid Technology: Present Advancements, Applications, and Obstacles. Curr Pharm Biotechnol. 2024;25:1000-1020.
Read More
Author biographies is not available.
Download
PDF
Statistic
Read Counter : 2 Download : 8